Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 13132Neoplasms 10477Carcinoma, Non-Small-Cell Lung 6870Prostatic Neoplasms 6268Colorectal Neoplasms 5945Lung Neoplasms 5102Multiple Myeloma 3576Pancreatic Neoplasms 3561Leukemia, Myeloid, Acute 3510Neoplasm Metastasis 3507Carcinoma, Hepatocellular 3271Ovarian Neoplasms 3168Melanoma 3139Stomach Neoplasms 3056Lymphoma 2982Head and Neck Neoplasms 2603Recurrence 2556Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Leukemia 2362Colonic Neoplasms 2327Brain Neoplasms 2310Lymphoma, Non-Hodgkin 2268Rectal Neoplasms 2191Uterine Cervical Neoplasms 2191Glioblastoma 2014Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1913Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1847Esophageal Neoplasms 1800

Interventions

aumolertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor × Clear all
NCT04216121 2024-07-01

LAT-FLOSI

Universitaire Ziekenhuizen KU Leuven

Recruiting
39 enrolled
Thoracic

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

NCT06102928 2023-10-26

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Kunming Medical University

Phase NA Recruiting
30 enrolled
Thoracic

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡